United States Biotechnology & Medical Research

Prometheus Biosciences Inc (RXDX)

Track

Track

Prometheus Biosciences Inc. experienced significant insider activity during early 2023. Executives, including the CEO and CFO, executed multiple planned sales of company stock. Additionally, a major shareholder divested a substantial position in March. The most recent recorded transaction occurred on April 5, 2023, marking over three months since any reported market movement.
Ticker: RXDX Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
No insider activity signals detected

Insider trades have not triggered unusual activity signals for this company.

Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Marshall Keith W Chief Financial Officer Officer
Transaction date
Planned sale
Price
44.32
Quantity 44,973 +6.2%
Value US$2,367,119
0.6
McKenna Mark C. Chairman, President & CEO Executive Director
Transaction date
Planned sale
Price
31.45
Quantity 70,833 -36.4%
Value US$4,828,284
Marshall Keith W Chief Financial Officer Officer
Transaction date
Planned sale
Price
122.13
Quantity 10,000 -50.5%
Value US$1,221,300
0.6
McKenna Mark C. Chairman, President & CEO Executive Director
Transaction date
Planned sale
Price
125.13
Quantity 10,620 -16.1%
Value US$1,328,881
0.6
McKenna Mark C. Chairman, President & CEO Executive Director
Transaction date
Planned sale
Price
125.26
Quantity 700 -1.3%
Value US$87,682
0.6
McKenna Mark C. Chairman, President & CEO Executive Director
Transaction date
Planned sale
Price
125.10
Quantity 13,680 -19.9%
Value US$1,711,368
0.6
McKenna Mark C. Chairman, President & CEO Executive Director
Transaction date
Planned sale
Price
119.87
Quantity 25,000 -31.2%
Value US$2,996,750
0.6
McKenna Mark C. Chairman, President & CEO Executive Director
Transaction date
Planned sale
Price
119.42
Quantity 25,000 -31.2%
Value US$2,985,500
Marshall Keith W Chief Financial Officer Officer
Transaction date
Planned sale
Price
119.38
Quantity 5,000 -33.8%
Value US$596,900
0.6
McKenna Mark C. Chairman, President & CEO Executive Director
Transaction date
Planned sale
Price
118.99
Quantity 25,000 -31.2%
Value US$2,974,750
Marshall Keith W Chief Financial Officer Officer
Transaction date
Planned sale
Price
119.00
Quantity 5,000 -33.8%
Value US$595,000
2.7
PERCEPTIVE ADVISORS LLC Large shareholder
Transaction date
Purchase
Price
19.00
Quantity 850,000 +34.5%
Value US$16,150,000
3.1
PAPA JOSEPH C Non-Executive Director
Transaction date
Purchase
Price
19.00
Quantity 15,000 +inf%
Value US$285,000
3.3
Adams Helen C. Non-Executive Director
Transaction date
Purchase
Price
19.00
Quantity 500 +inf%
Value US$9,500
2.7
RTW INVESTMENTS, LP Large shareholder
Transaction date
Purchase
Price
19.00
Quantity 800,000 +inf%
Value US$15,200,000
Stenhouse Mark Chief Operating Officer Officer
Transaction date
Purchase
Price
19.00
Quantity 14,000 +inf%
Value US$266,000
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2023-04-07 2023-04-05 PlS Planned sale
Marshall Keith W

Chief Financial Officer

Officer
44,973 +6.2%
44.32
US$2,367,119 		44,973 +6.2% 44.32 US$2,367,119
2023-03-17 2023-03-15 PlS Planned sale
0.6
McKenna Mark C.

Chairman, President & CEO

Executive Director
70,833 -36.4%
31.45
US$4,828,284 		70,833 -36.4% 31.45 US$4,828,284
2023-03-08 2023-03-08 PrS Proposed sale
Cedars Sinai Intellectual Property Company

10% Stockholder

Large shareholder
34,528
162.92
US$1,337,787 		34,528 162.92 US$1,337,787
2023-03-08 2023-03-08 S Sale
Cedars Sinai Intellectual Property Co
Large shareholder
865,000 -17.8%
114.59
US$99,120,350 		865,000 -17.8% 114.59 US$99,120,350
2023-03-08 2023-03-06 PlS Planned sale
Marshall Keith W

Chief Financial Officer

Officer
10,000 -50.5%
122.13
US$1,221,300 		10,000 -50.5% 122.13 US$1,221,300
2023-03-03 2023-03-03 PlS Planned sale
0.6
McKenna Mark C.

Chairman, President & CEO

Executive Director
10,620 -16.1%
125.13
US$1,328,881 		10,620 -16.1% 125.13 US$1,328,881
2023-03-03 2023-03-01 PlS Planned sale
0.6
McKenna Mark C.

Chairman, President & CEO

Executive Director
700 -1.3%
125.26
US$87,682 		700 -1.3% 125.26 US$87,682
2023-02-17 2023-02-17 PlS Planned sale
0.6
McKenna Mark C.

Chairman, President & CEO

Executive Director
13,680 -19.9%
125.10
US$1,711,368 		13,680 -19.9% 125.10 US$1,711,368
2023-02-17 2023-02-16 PlS Planned sale
0.6
McKenna Mark C.

Chairman, President & CEO

Executive Director
25,000 -31.2%
119.87
US$2,996,750 		25,000 -31.2% 119.87 US$2,996,750
2023-02-17 2023-02-15 PlS Planned sale
0.6
McKenna Mark C.

Chairman, President & CEO

Executive Director
25,000 -31.2%
119.42
US$2,985,500 		25,000 -31.2% 119.42 US$2,985,500
2023-02-17 2023-02-15 PlS Planned sale
Marshall Keith W

Chief Financial Officer

Officer
5,000 -33.8%
119.38
US$596,900 		5,000 -33.8% 119.38 US$596,900
2023-01-19 2023-01-17 PlS Planned sale
0.6
McKenna Mark C.

Chairman, President & CEO

Executive Director
25,000 -31.2%
118.99
US$2,974,750 		25,000 -31.2% 118.99 US$2,974,750
2023-01-19 2023-01-17 PlS Planned sale
Marshall Keith W

Chief Financial Officer

Officer
5,000 -33.8%
119.00
US$595,000 		5,000 -33.8% 119.00 US$595,000
2021-03-18 2021-03-16 B Purchase
3.7
Cormorant Asset Management, LP
375,000 +20.3%
19.00
US$7,125,000 		375,000 +20.3% 19.00 US$7,125,000
2021-03-17 2021-03-16 B Purchase
Point72 Biotech Private Investments, LLC

Former 10% Owner
800,000 +43.3%
19.00
US$15,200,000 		800,000 +43.3% 19.00 US$15,200,000
2021-03-16 2021-03-16 B Purchase
2.7
PERCEPTIVE ADVISORS LLC
Large shareholder
850,000 +34.5%
19.00
US$16,150,000 		850,000 +34.5% 19.00 US$16,150,000
2021-03-16 2021-03-16 B Purchase
3.1
PAPA JOSEPH C
Non-Executive Director
15,000 +inf%
19.00
US$285,000 		15,000 +inf% 19.00 US$285,000
2021-03-16 2021-03-16 B Purchase
3.3
Adams Helen C.
Non-Executive Director
500 +inf%
19.00
US$9,500 		500 +inf% 19.00 US$9,500
2021-03-16 2021-03-16 B Purchase
2.7
RTW INVESTMENTS, LP
Large shareholder
800,000 +inf%
19.00
US$15,200,000 		800,000 +inf% 19.00 US$15,200,000
2021-03-16 2021-03-16 B Purchase
Stenhouse Mark

Chief Operating Officer

Officer
14,000 +inf%
19.00
US$266,000 		14,000 +inf% 19.00 US$266,000
Explore more

More insider trading research around Prometheus Biosciences Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America